February 2, 2017 / PRESS RELEASE
U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
January 27, 2017 / PRESS RELEASE
AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results
